drug

sertraline-primary

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Northwell Health, Early Treatment Program at Lenox Hill
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
NCT00169988—Completed

KOLs & investigators

2
Christoph U. Correll, MDKOL score 96
Barbara A Cornblatt, PhDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Northwell Health, Early Treatment Program at Lenox Hill
company
trial
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
NA
trial
indication
Schizotypal Personality Disorder
indication
Prodromal Schizophrenia
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
KOL
Christoph U. Correll, MD
KOL score 96
person
Barbara A Cornblatt, PhD
KOL score 5
person